SuperworthIN8BIO price to book ratio INAB
Market value divided by the book value of the company's net assets, since 2021.
- Today, Oct 23, 2026
- 0.6×
- 5-year median
- 1.4×
- Against its 5-year history
- 9th
- percentile: 0 is its lowest day, 100 its highest
- 5-year range
- 0.2× to 5.7×
- Peer median
- 1.6×
IN8BIO's price to book ratio is 0.6× as of Oct 23, 2026.
That is below its 5-year median of 1.4×, lower than on 91% of days in the last 5 years.
Over that time it ranged from 0.2× in Apr 2026 to 5.7× in May 2023.
The median for 7 healthcare stocks of a similar size is 1.6×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 0.6× | 0.2× | 0.9× |
| 2025 | 0.8× | 0.4× | 2.7× |
| 2024 | 2.3× | 0.8× | 3.4× |
| 2023 | 2.5× | 1.0× | 5.7× |
| 2022 | 1.9× | 1.0× | 2.0× |
| 2021 | 1.9× | 1.9× | 3.7× |
Against its peers
Companies in Healthcare nearest IN8BIO's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| INABIN8BIO | 0.6× |
| NEPHNephros | 3.2× |
| ATNMActinium Pharmaceuticals | 1.6× |
| APTAlpha Pro Tech | 0.9× |
| SPROSpero Therapeutics | 1.5× |
| LFVNLifevantage | 2.2× |
| ICCCImmucell | 3.0× |
| KEQUKewaunee Scientific | 1.3× |
| Peer median | 1.6× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on IN8BIO
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.